

ISO 18562-1:2024-03 (E)

Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 1: Evaluation and testing within a risk management process

Contents	Page
Foreword.....	iv
Introduction.....	v
1 Scope.....	1
2 Normative references.....	2
3 Terms and definitions.....	2
4 General principles applying to <i>biocompatibility</i> evaluation of <i>medical devices</i>.....	11
4.1 General.....	11
4.2 <i>Type tests</i>	14
4.3 <i>Biocompatibility hazard</i> identification.....	14
4.4 Extent of <i>risk assessment</i>	15
4.5 Biological evaluation plan.....	15
4.6 Selection of tests.....	17
4.7 Subsequent evaluation.....	18
5 Contamination of breathing gas from <i>gas pathways</i>.....	19
5.1 Duration of use.....	19
5.2 <i>Particulate matter (PM)</i> emissions.....	19
5.3 <i>Volatile organic substance</i> emissions.....	20
5.4 <i>Leachables</i> in condensate.....	20
6 Adjustment of <i>exposure dose</i> and <i>inhalation dose</i> for different <i>patient groups</i>.....	20
6.1 General considerations.....	20
6.2 Adjustment for different <i>patient groups</i>	20
7 Deriving <i>tolerable exposure (TE)</i> for <i>VOS</i>.....	21
7.1 General <i>process</i>	21
7.2 For <i>medical devices</i> intended for limited exposure use (≤ 24 h) and prolonged exposure use (>24 h but <30 d).....	22
7.3 For <i>medical devices</i> intended for long-term exposure (≥ 30 d).....	23
8 Determining values for <i>leachables</i> in condensate.....	23
8.1 General.....	23
8.2 Adjustments for different <i>patient groups</i>	24
8.3 <i>Exposure dose</i> estimate for condensate.....	24
9 Risk control.....	24
10 Benefit-risk analysis.....	24
11 Biological evaluation report.....	25
Annex A (informative) Rationale and guidance.....	26
Annex B (informative) Reference to the IMDRF <i>essential principles</i> and labelling guidances.....	28
Annex C (informative) Reference to the <i>essential principles</i>.....	30
Annex D (informative) Terminology — Alphabetized index of defined terms.....	31
Bibliography.....	33